Literature DB >> 26784657

Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis.

Bharati Pandey1, Sonam Grover2, Chetna Tyagi3, Sukriti Goyal4, Salma Jamal4, Aditi Singh5, Jagdeep Kaur1, Abhinav Grover6.   

Abstract

The latest resurrection of drug resistance poses serious threat to the treatment and control of the disease. Mutations have been detected in panD gene in the Mycobacterium tuberculosis (Mtb) strains. Mutation of histidine to arginine at residue 21 (H21R) and isoleucine to valine at residue 29 (I49V) in the non-active site of panD gene has led to PZA resistance. This study will help in reconnoitering the mechanism of pyrazinamide (PZA) resistance caused due to double mutation identified in the panD gene of M. tuberculosis clinical isolates. It is known that panD gene encodes aspartate decarboxylase essential for β-alanine synthesis that makes it a potential therapeutic drug target for tuberculosis treatment. The knowledge about the molecular mechanism conferring drug resistance in M. tuberculosis is scarce, which is a significant challenge in designing successful therapeutic drug. In this study, structural and dynamic repercussions of H21R-I49V double mutation in panD complexed with PZA have been corroborated through docking and molecular dynamics based simulation. The double mutant (DM) shows low docking score and thus, low binding affinity for PZA as compared to the native protein. It was observed that the mutant protein exhibits more structural fluctuation at the ligand binding site in comparison to the native type. Furthermore, the flexibility and compactness analyses indicate that the double mutation influence interaction of PZA with the protein. The hydrogen-bond interaction patterns further supported our results. The covariance and PCA analysis elucidated that the double mutation affects the collective motion of residues in phase space. The results have been presented with an explanation for the induced drug resistance conferred by the H21R-I49V double mutation in panD gene and gain valuable insight to facilitate the advent of efficient therapeutics for combating resistance against PZA.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Docking; Pyrazinamide; RMSD; RMSF; Simulation

Mesh:

Substances:

Year:  2016        PMID: 26784657     DOI: 10.1016/j.gene.2016.01.024

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  12 in total

1.  A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.

Authors:  Adam N Yadon; Kashmeel Maharaj; John H Adamson; Yi-Pin Lai; James C Sacchettini; Thomas R Ioerger; Eric J Rubin; Alexander S Pym
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

2.  Molecular dynamics simulations revealed structural differences among WRKY domain-DNA interaction in barley (Hordeum vulgare).

Authors:  Bharati Pandey; Abhinav Grover; Pradeep Sharma
Journal:  BMC Genomics       Date:  2018-02-12       Impact factor: 3.969

Review 3.  Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.

Authors:  Navisha Dookie; Santhuri Rambaran; Nesri Padayatchi; Sharana Mahomed; Kogieleum Naidoo
Journal:  J Antimicrob Chemother       Date:  2018-05-01       Impact factor: 5.790

4.  Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents.

Authors:  Jan Zitko; Alžběta Mindlová; Ondřej Valášek; Ondřej Jand'ourek; Pavla Paterová; Jiří Janoušek; Klára Konečná; Martin Doležal
Journal:  Molecules       Date:  2018-09-18       Impact factor: 4.411

5.  The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot .

Authors:  Pavel Mucaji; Atanas G Atanasov; Andrzej Bak; Violetta Kozik; Karolina Sieron; Mark Olsen; Weidong Pan; Yazhou Liu; Shengchao Hu; Junjie Lan; Norbert Haider; Robert Musiol; Jan Vanco; Marc Diederich; Seungwon Ji; Jan Zitko; Dongdong Wang; Danica Agbaba; Katarina Nikolic; Slavica Oljacic; Jelica Vucicevic; Daniela Jezova; Anna Tsantili-Kakoulidou; Fotios Tsopelas; Constantinos Giaginis; Teresa Kowalska; Mieczyslaw Sajewicz; Jerzy Silberring; Przemyslaw Mielczarek; Marek Smoluch; Izabela Jendrzejewska; Jaroslaw Polanski; Josef Jampilek
Journal:  Molecules       Date:  2017-10-28       Impact factor: 4.411

6.  Synthesis of Novel Pyrazinamide Derivatives Based on 3-Chloropyrazine-2-carboxamide and Their Antimicrobial Evaluation.

Authors:  Ondrej Jandourek; Marek Tauchman; Pavla Paterova; Klara Konecna; Lucie Navratilova; Vladimir Kubicek; Ondrej Holas; Jan Zitko; Martin Dolezal
Journal:  Molecules       Date:  2017-02-02       Impact factor: 4.411

7.  Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold.

Authors:  Jan Zitko; Ondřej Jand'ourek; Pavla Paterová; Lucie Navrátilová; Jiří Kuneš; Jarmila Vinšová; Martin Doležal
Journal:  Medchemcomm       Date:  2018-02-22       Impact factor: 3.597

8.  Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.

Authors:  Sharad Verma; Sukriti Goyal; Anchala Kumari; Aditi Singh; Salma Jamal; Abhinav Grover
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

9.  Alanine mutation of the catalytic sites of Pantothenate Synthetase causes distinct conformational changes in the ATP binding region.

Authors:  Bharati Pandey; Sonam Grover; Sukriti Goyal; Anchala Kumari; Aditi Singh; Salma Jamal; Jagdeep Kaur; Abhinav Grover
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

Review 10.  Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Authors:  H M Adnan Hameed; Md Mahmudul Islam; Chiranjibi Chhotaray; Changwei Wang; Yang Liu; Yaoju Tan; Xinjie Li; Shouyong Tan; Vincent Delorme; Wing W Yew; Jianxiong Liu; Tianyu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-10       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.